Eli Lilly agreed to acquire exclusive global rights to MeiraGTx’s AAV‑AIPL1 gene therapy for Leber congenital amaurosis 4 (LCA4), paying $75 million up front with up to $400 million in milestones. MeiraGTx’s Phase I data published in The Lancet showed unprecedented vision gains in treated children, and Lilly said it will pursue regulatory filings in the US and EU. Lilly also gained access to a broader suite of retinal gene‑therapy technologies as part of the pact, and characterized ophthalmology as a strategic growth area. MeiraGTx will receive development and commercial milestones plus royalties; executives framed the deal as rapid scale-up of a late‑stage genetic medicine into Lilly’s global commercial footprint. Investors and industry partners will watch regulatory sequencing closely: MeiraGTx intends submissions in MHRA and FDA jurisdictions, leveraging published Phase I results. The transaction highlights continued big‑pharma appetite for durable, one‑time genetic medicines in rare retinal diseases and underlines the premium for clinical proof of vision restoration.